Equibles does not estimate personal net worth.
Get an email with a short summary when Rigel Pharmaceuticals Inc publishes a filing, an earnings call transcript or a press release.
Get RIGL alertsDave Santos has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Rigel Pharmaceuticals Inc on November 5, 2026. Rigel Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rigel Pharmaceuticals Inc includes Raul R. Rodriguez (CEO and Board Member), Raul Rodriguez (CEO and Board Member), Dean Schorno (CFO) and 7 others.
“On slide 8, you'll see our four commercial products, Vepinu, Tavalis, Reslidia, and Givretto. Moving to slide 9, our net product sales were $72.3 million for the third quarter of 2026, an increase of 13% compared to the third quarter of 2025, primarily driven by the addition of Vepinu during the third quarter.”
“On slide eight, you'll see our three commercial products, Tavalis, Givretto, and Riz Lydia.”
“And thank you, Dr. Hamilton, for the overview of Vepinu's novel ProTac mechanism of action and impressive clinical data from Veritac 2. On to slide 36. To begin, let me reiterate how excited we are with the potential of adding Vepinu to our commercial portfolio.”
“On slide 10, you'll see our three commercial products, Tabalis, Gavretto, and Reslinia. Moving to slide 11, we are pleased with the year-over-year growth in revenues in the first quarter of 2026, continuing our trend of growing each quarter's sales over the previous year, as evidenced by this slide.”
“On slide 10 you'll see our three commercial products. Tavalis, Gavretto and ResLydia. Moving to slide 11 we are thrilled to report full-year results for 2025 and how our net sales have consistently grown over the last five years.”
Source not stated
Biotechnology · Healthcare
